Reaction
Epstein-Barr Virus Associated Lymphoma reporting signals
As of the last recalculation, Epstein-Barr Virus Associated Lymphoma appears in 583 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 70.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alemtuzumab | 36 | 70.8 | 70.9 |
| Mycophenolate Mofetil | 159 | 57.1 | 57.2 |
| Mycophenolate Mofetil Hydrochloride | 159 | 57.0 | 57.1 |
| Basiliximab | 16 | 49.9 | 50.0 |
| Mycophenilic Acid | 26 | 46.8 | 46.9 |
| Everolimus Tablets | 18 | 39.5 | 39.6 |
| Vincristine Sulfate | 30 | 38.5 | 38.5 |
| Azathioprine | 75 | 34.7 | 34.8 |
| Mycophenolic Acid | 29 | 34.0 | 34.0 |
| Tacrolimus Ointment 0.1% | 97 | 33.2 | 33.2 |
| Tacrolimus Extended-Release Capsules | 97 | 33.1 | 33.1 |
| Doxorubicin | 72 | 32.8 | 32.8 |
| Sirolimus | 12 | 32.4 | 32.5 |
| Adalimumab-Fkjp | 38 | 31.3 | 31.3 |
| Adalimumab-Aaty | 38 | 30.6 | 30.6 |
| Tofacitinib Citrate | 11 | 30.5 | 30.5 |
| Tacrolimus | 105 | 29.0 | 29.0 |
| Ganciclovir | 8 | 28.3 | 28.3 |
| Brentuximab Vedotin | 8 | 28.2 | 28.3 |
| Bleomycin Sulfate | 8 | 28.0 | 28.0 |
| Adalimumab-Adaz | 38 | 27.4 | 27.5 |
| Ganciclovir Sodium | 8 | 27.4 | 27.4 |
| Mercaptopurine | 13 | 27.4 | 27.4 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 26.8 | 26.8 |
| Itraconazole | 8 | 24.8 | 24.8 |
| Cyclophosphamide Injection, Solution | 95 | 22.7 | 22.7 |
| Cyclophosphamide | 95 | 22.7 | 22.7 |
| Cyclophosphamide For Injection | 95 | 22.7 | 22.7 |
| Bendamustine Hcl | 8 | 18.7 | 18.7 |
| Daratumumab | 14 | 12.8 | 12.8 |